Product Description
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody that selectively targets ?4?7 integrin expressed on the surface of T and B cell lymphocytes and prevents the association of the integrin with its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1). This inhibits the inflammatory activity of the lymphocytic cells and its migration into the gut lamina propria and gut-associated lymphoid tissue (GALT). Vedolizumab was developed by Millennium Pharmaceuticals and received FDA approval in 2014 for the treatment of ulcerative colitis and Crohns disease. Vedolizumab is marketed under the trade name of Entyvio®
Biovision | A2140 | Anti-?4?7 Integrin (Vedolizumab), Humanized Antibody DataSheet
Antibody Target: ?4?7 Integrin
Target Alternative Name: LDP 02, LDP-02, LDP02, MLN-0002, MLN-02, MLN0002, MLN02, ENTYVIO, ?4?7, ITGA4/ITGB7
Tag Line: Vedolizumab is a humanized monoclonal antibody that binds to ?4?7 integrin expressed on the surface of T and B lymphocytes and prevents gastrointestinal inflammatory activity. The monoclonal antibody received approval from the FDA for the treatment of ulcerative colitis and Crohn's disease
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Vedolizumab
Accession #: DB09033, DB05802
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application: In vitro studies
Positive Control:
Application And Usages: In vitro studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE